ABCB1 p.Asn296Cys
| Predicted by SNAP2: | A: D (75%), C: D (75%), D: D (71%), E: D (85%), F: D (85%), G: N (72%), H: D (85%), I: D (85%), K: D (75%), L: D (75%), M: D (85%), P: D (85%), Q: D (63%), R: D (91%), S: D (59%), T: D (80%), V: D (85%), W: D (91%), Y: D (85%), |
| Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] The packing of the transmembrane segments of human... J Biol Chem. 2000 Feb 25;275(8):5253-6. Loo TW, Clarke DM
The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis.
J Biol Chem. 2000 Feb 25;275(8):5253-6., 2000-02-25 [PMID:10681495]
Abstract [show]
Residues from several transmembrane (TM) segments of P-glycoprotein (P-gp) likely form the drug-binding site(s). To determine the organization of the TM segments, pairs of cysteine residues were introduced into the predicted TM segments of a Cys-less P-gp, and the mutant protein was subjected to oxidative cross-linking. In SDS gels, the cross-linked product migrated with a slower mobility than the native protein. The cross-linked products were not detected in the presence of dithiothreitol. Cross-linking was observed in 12 of 125 mutants. The pattern of cross-linking suggested that TM6 is close to TMs 10, 11, and 12, while TM12 is close to TMs 4, 5, and 6. In some mutants the presence of drug substrate colchicine, verapamil, cyclosporin A, or vinblastine either enhanced or inhibited cross-linking. Cross-linking was inhibited in the presence of ATP plus vanadate. These results suggest that the TM segments critical for drug binding must be close to each other and exhibit different conformational changes in response to binding of drug substrate or vanadate trapping of nucleotide. Based on these results, we propose a model for the arrangement of the TM segments.
Comments [show]
None has been submitted yet.
No. Sentence Comment
77 In these cross-linking experiments, the amount of oxidant was lowered by 10-fold (0.2 mM), and the minimum temperature required to induce cross-TABLE I Cross-linking analysis of P-gp Cross-linking of S993C (TM12) with residues in the following TM: TM1 TM2 TM3 TM4 TM5 M51C -a Y130C - G185C - G226C - I293C - V52C - I131C - I186C - L227C ϩb T294C - V53C - Q132C - G187C - S228C - A295C ϩ G54C - V133C - D188C - A229C - N296C - T55C - S134C - K189C - A230C - I297C - L56C - F135C - I190C - V231C ϩ S298C - A57C - W136C - G191C - W232C ϩ I299C ϩ A58C - C137C - M192C - A233C ϩ G300C - I59C - L138C - F193C - K234C - A301C - I60C - A139C - F194C - I235C ϩ A302C - H61C - A140C - Q195C - L236C ϩ F303C - G141C - S196C - S237C - L304C - Cross-linking of P350C (TM6) with residues in the following TM: TM7 TM8 TM9 TM10 TM11 F711C - F770C - A828C - I867C - A935C - V712C - F771C - I829C - I868C - H936C - V713C - L772C - G830C - A869C - I937C - G714C - Q773C - S831C - I870C - F938C - V715C - G774C - R832C - A871C - G939C ϩ F716C - F775C - L833C - G872C - I940C - C717C - T776C - A834C - V873C - T941C - A718C - F777C - V835C - V874C ϩ F942C - I719C - G778C - I836C - E875C ϩ S943C - I720C - K779C - T837C - M876C ϩ F944C - N721C - A780C - Q838C - K877C - T945C - G722C - G781C - N839C - M878C - Q946C - G723C - E782C - I840C - L879C - A947C - I783C - a -, no cross-linked product detected in SDS-PAGE. b ϩ, cross-linked product detected in SDS-PAGE.
X
ABCB1 p.Asn296Cys 10681495:77:430
status: NEW[hide] Location of the rhodamine-binding site in the huma... J Biol Chem. 2002 Nov 15;277(46):44332-8. Epub 2002 Sep 9. Loo TW, Clarke DM
Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein.
J Biol Chem. 2002 Nov 15;277(46):44332-8. Epub 2002 Sep 9., 2002-11-15 [PMID:12223492]
Abstract [show]
The human multidrug resistance P-glycoprotein (P-gp) pumps a wide variety of structurally diverse compounds out of the cell. It is an ATP-binding cassette transporter with two nucleotide-binding domains and two transmembrane (TM) domains. One class of compounds transported by P-gp is the rhodamine dyes. A P-gp deletion mutant (residues 1-379 plus 681-1025) with only the TM domains retained the ability to bind rhodamine. Therefore, to identify the residues involved in rhodamine binding, 252 mutants containing a cysteine in the predicted TM segments were generated and reacted with a thiol-reactive analog of rhodamine, methanethiosulfonate (MTS)-rhodamine. The activities of 28 mutants (in TMs 2-12) were inhibited by at least 50% after reaction with MTS-rhodamine. The activities of five mutants, I340C(TM6), A841C(TM9), L975C(TM12), V981C(TM12), and V982C(TM12), however, were significantly protected from inhibition by MTS-rhodamine by pretreatment with rhodamine B, indicating that residues in TMs 6, 9, and 12 contribute to the binding of rhodamine dyes. These results, together with those from previous labeling studies with other thiol-reactive compounds, dibromobimane, MTS-verapamil, and MTS-cross-linker substrates, indicate that common residues are involved in the binding of structurally different drug substrates and that P-gp has a common drug-binding site. The results support the "substrate-induced fit" hypothesis for drug binding.
Comments [show]
None has been submitted yet.
No. Sentence Comment
138 In contrast, four mutants (N296C, G300C, Y310C, and F314C) were inhibited by Ͼ70% with MTS-rhodamine.
X
ABCB1 p.Asn296Cys 12223492:138:27
status: NEW[hide] Disulfide cross-linking analysis shows that transm... J Biol Chem. 2004 Feb 27;279(9):7692-7. Epub 2003 Dec 10. Loo TW, Bartlett MC, Clarke DM
Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane.
J Biol Chem. 2004 Feb 27;279(9):7692-7. Epub 2003 Dec 10., 2004-02-27 [PMID:14670948]
Abstract [show]
Human P-glycoprotein (P-gp) transports a wide variety of structurally diverse compounds out of the cell. Knowledge about the packing of the transmembrane (TM) segments is essential for understanding the mechanism of drug recognition and transport. We used cysteine-scanning mutagenesis and disulfide cross-linking analysis to determine which TM segment in the COOH half of P-gp was close to TMs 5 and 6 since these segments in the NH(2) half are important for drug binding. An active Cys-less P-gp mutant cDNA was used to generate 240 double cysteine mutants that contained 1 cysteine in TMs 5 or 6 and another in TMs 7 or 8. The mutants were subjected to oxidative cross-linking analysis. No disulfide cross-linking was observed in the 140 TM6/TM7 or TM6/TM8 mutants. By contrast, cross-linking was detected in several P-gp TM5/TM8 mutants. At 4 degrees C, when thermal motion is low, P-gp mutants N296C(TM5)/G774C(TM8), I299C(TM5)/F770C(TM8), I299C(TM5)/G774C(TM8), and G300C(TM5)/F770C(TM8) showed extensive cross-linking with oxidant. These mutants retained drug-stimulated ATPase activity, but their activities were inhibited after treatment with oxidant. Similarly, disulfide cross-linking was inhibited by vanadate trapping of nucleotide. These results indicate that significant conformational changes must occur between TMs 5 and 8 during ATP hydrolysis. We revised the rotational symmetry model for TM packing based on our results and by comparison to the crystal structure of MsbA (Chang, G. (2003) J. Mol. Biol. 330, 419-430) such that TM5 is adjacent to TM8, TM2 is adjacent to TM11, and TMs 1 and 7 are next to TMs 6 and 12, respectively.
Comments [show]
None has been submitted yet.
No. Sentence Comment
101 Eleven mutants (I293C/F775C, N296C/F770C, N296C/G774C, I297C/F771C, I297C/G774C, I299C/F770C, I299C/G774C, G300C/F767C, G300C/F770C, G300C/F771C, and G300C/G774C) showed relatively strong (Ͼ50%) cross-linking (Table I).
X
ABCB1 p.Asn296Cys 14670948:101:29
status: NEWX
ABCB1 p.Asn296Cys 14670948:101:42
status: NEW105 Six mutants (A295C/ G774C, N296C/F771C, N296C/Q773C, N296C/F775C, I297C/ F770C, and G300C/F775C) showed relatively weak (Ͻ50%) cross-linking (Table I).
X
ABCB1 p.Asn296Cys 14670948:105:27
status: NEWX
ABCB1 p.Asn296Cys 14670948:105:40
status: NEWX
ABCB1 p.Asn296Cys 14670948:105:53
status: NEW110 The eleven mutants (I293C/F775C, N296C/F770C, N296C/G774C, I297C/F771C, I297C/G774C, I299C/F770C, I299C/G774C, G300C/F767C, G300C/F770C, G300C/F771C, and G300C/G774C) that showed relatively strong cross-linking at 37 °C were subjected to cross-linking at 22 and 4 °C.
X
ABCB1 p.Asn296Cys 14670948:110:33
status: NEWX
ABCB1 p.Asn296Cys 14670948:110:46
status: NEW111 Only four mutants (N296C/G774C, I299C/F770C, I299C/G774C, and G300C/F770C) still showed cross-linking at 22 and 4 °C.
X
ABCB1 p.Asn296Cys 14670948:111:19
status: NEW112 Mutants I293C/F775C, N296C/ F770C, I297C/G774C, G300C/F771C, and G300C/G774C were cross-linked only at 22 °C, whereas mutants I297C/F771C and G300C/F767C showed no cross-linking at either 22 or 4 °C. Fig. 3 shows the temperature-dependent cross-linking of mutants N296C/G774C, I299C/F770C, I299C/G774C, and G300C/ F770C.
X
ABCB1 p.Asn296Cys 14670948:112:21
status: NEWX
ABCB1 p.Asn296Cys 14670948:112:274
status: NEW114 All four mutants were cross-linked at a slower rate at 4 °C, with most of the cross-linked product detected by 8 min. Fig. 3 also shows that in mutant N296C/ F770C about 50% of the cross-linked product was detected by 8 min at 22 °C, and cross-linked product was barely detectable after 32 min at 4 °C.
X
ABCB1 p.Asn296Cys 14670948:114:156
status: NEW115 Mutants N296C/G774C, I299C/F770C, I299C/G774C, and G300C/F770C were selected for further analysis because they were cross-linked at 37, 22, and 4 °C.
X
ABCB1 p.Asn296Cys 14670948:115:8
status: NEW117 By contrast, no cross-linked product was detected in the single cysteine mutants, N296C, I299C, G300C, F770C, and G774C, when oxidant was added at these temperatures (data not shown).
X
ABCB1 p.Asn296Cys 14670948:117:82
status: NEW118 To test if the mutants N296C/G774C, I299C/F770C, I299C/ G774C, and G300C/F770C retained the ability to interact with drug substrates, they were expressed in HEK 293 cells, isolated by nickel-chelate chromatography, mixed with lipid, and assayed for drug-stimulated ATPase activity.
X
ABCB1 p.Asn296Cys 14670948:118:23
status: NEW124 The verapamiland demecolcine-stimulated ATPase activities rel- TABLE I Cross-linking between residues in TMs 5 and 8 TM5 TM 8 F767C I768C T769C F770C F771C L772C Q773C G774C F775C T776C I293C -a - - - - - - - ϩϩb - T294C - - - - - - - - - - A295C - - - - - - - ϩ - - N296C - - - ϩϩb ϩ - ϩ ϩϩc ϩ - I297C - - - ϩd ϩϩ - - ϩϩb - - S298C - - - - - - - - - - I299C - - - ϩϩc - - - ϩϩc - - G300C ϩϩe - - ϩϩc ϩϩb - - ϩϩb ϩ - A301C - - - - - - - - - - A302C - - - - - - - - - - a No cross-linked product detected in SDS-PAGE gels at 37 °C. b Cross-linked product was also detected at 22 °C. c Cross-linked product was also detected at 22 °C and at 4 °C. d Relatively weak cross-linking (Ͻ50% of P-gp cross-linked) at 37 °C. e Relatively strong cross-linking (Ͼ50% of P-gp cross-linked) at 37 °C. FIG. 2.
X
ABCB1 p.Asn296Cys 14670948:124:285
status: NEW126 Membranes were prepared from HEK 293 cells expressing P-gp mutants I297C (A), F771C (A), I297C/F771C (A), N296C/F770C (B), or I297C/F770C (B).
X
ABCB1 p.Asn296Cys 14670948:126:106
status: NEW130 ative to that of Cys-less P-gp were 65 and 62%, 68 and 51%, and 57 and 79% for mutants N296C/G774C, I299C/G774C, and G300C/F770C, respectively.
X
ABCB1 p.Asn296Cys 14670948:130:87
status: NEW131 We then tested whether cross-linking affected the verapamil-stimulated ATPase activities of mutants N296C/G774C, I299C/ F770C, I299C/G774C, and G300C/F770C.
X
ABCB1 p.Asn296Cys 14670948:131:100
status: NEW134 By contrast, the verapamil-stimulated ATPase activities of mutants N296C/G774C, I299C/ F770C, I299C/G774C, and G300C/F770C were inhibited by 60-80% after treatment with oxidant. These results suggest that cross-linking inhibits conformational changes in P-gp during ATP hydrolysis (47, 50).
X
ABCB1 p.Asn296Cys 14670948:134:67
status: NEW135 Because there is evidence that TM5 lines the drug binding pocket of P-gp (44), we tested whether drug substrates that stimulate (demecolcine and verapamil) or inhibit (cyclosporin A) (29) ATPase activity would affect the cross-linking pattern observed in mutants N296C/G774C, I299C/F770C, I299C/ G774C, and G300C/F770C.
X
ABCB1 p.Asn296Cys 14670948:135:263
status: NEW147 Accordingly, the effect of vanadate trapping on cross-linking of mutants N296C/G774C, I299C/ F770C, I299C/G774C, and G300C/F770C was examined.
X
ABCB1 p.Asn296Cys 14670948:147:73
status: NEW151 Effect of temperature on cross-linking. Membranes were prepared from HEK 293 cells expressing P-gp mutants N296C/G774C, I299C/F770C, I299C/G774C, G300C/F770C, or N296C/F770C.
X
ABCB1 p.Asn296Cys 14670948:151:107
status: NEWX
ABCB1 p.Asn296Cys 14670948:151:162
status: NEW157 Histidine-tagged Cys-less (C-less) P-gp and mutants N296C/ G774C, I299C/F770C, I299C/G774C, or G300C/F770C were isolated by nickel-chelate chromatography.
X
ABCB1 p.Asn296Cys 14670948:157:52
status: NEW162 Effect of drug substrates on cross-linking. Membranes were prepared from HEK 293 cells expressing P-gp mutants N296C/ G774C, I299C/F770C, I299C/G774C, or G300C/F770C.
X
ABCB1 p.Asn296Cys 14670948:162:111
status: NEW191 The model may explain why the presence of drug substrates had relatively little effect on cross-linking of mutants N296C/ G774C, I299C/F770C, I299C/G774C, and G300C/F770C.
X
ABCB1 p.Asn296Cys 14670948:191:115
status: NEW197 Membranes from HEK 293 cells expressing P-gp mutants N296C/G774C, I299C/F770C, I299C/G774C, or G300C/F770C were preincubated at 37 °C for 10 min in the presence (ϩ) or absence (-) of ATP and MgCl2 plus sodium vanadate (ATP/VO4).
X
ABCB1 p.Asn296Cys 14670948:197:53
status: NEW211 For example, vanadate trapping of nucleotide nearly abolished cross-linking in mutants N296C/ G774C, I299C/F770C, I299C/G774C, and G300C/F770C (Fig. 6), although cross-linking inhibited drug-stimulated ATPase activity.
X
ABCB1 p.Asn296Cys 14670948:211:87
status: NEW[hide] Val133 and Cys137 in transmembrane segment 2 are c... J Biol Chem. 2004 Apr 30;279(18):18232-8. Epub 2004 Jan 28. Loo TW, Bartlett MC, Clarke DM
Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein.
J Biol Chem. 2004 Apr 30;279(18):18232-8. Epub 2004 Jan 28., 2004-04-30 [PMID:14749322]
Abstract [show]
P-glycoprotein (P-gp; ABCB1) transports a wide variety of structurally diverse compounds out of the cell. The protein has two homologous halves joined by a linker region. Each half consists of a transmembrane (TM) domain with six TM segments and a nucleotide-binding domain. The drug substrate-binding pocket is at the interface between the TM segments in each half of the protein. Preliminary studies suggested that the arrangement of the two halves of P-gp shows rotational symmetry (i.e. "head-to-tail" arrangement). Here, we tested this model by determining whether the cytoplasmic ends of TM2 and TM3 in the N-terminal half are in close contact with TM11 in the C-terminal half. Mutants containing a pair of cysteines in TM2/TM11 or TM3/TM11 were subjected to oxidative cross-linking with copper phenanthroline. Two of the 110 TM2/TM11 mutants, V133C(TM2)/G939C(TM11) and C137C(TM2)/A935C (TM11), were cross-linked at 4 degrees C, when thermal motion is reduced. Cross-linking was specific since no cross-linked product was detected in the 100 double Cys TM3/TM11 mutants. Vanadate trapping of nucleotide or the presence of some drug substrates inhibited cross-linking of mutants V133C(TM2)/G939C(TM11) and C137C(TM2)/A935C(TM11). Cross-linking of TM2 and TM11 also blocked drug-stimulated ATPase activity. The close proximity of TM2/TM11 and TM5/TM8 (Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) J. Biol. Chem. 279, 7692-7697) indicates that these regions between the two halves must enclose the drug-binding pocket at the cytoplasmic side of P-gp. They may form the "hinges" required for conformational changes during the transport cycle.
Comments [show]
None has been submitted yet.
No. Sentence Comment
176 A, membranes were prepared from HEK 293 cells expressing P-gp mutant V133C(TM2)/G939C(TM11), C137C(TM2)/A935C(TM11), or N296C- (TM5)/G774C(TM8).
X
ABCB1 p.Asn296Cys 14749322:176:120
status: NEW[hide] The W232R suppressor mutation promotes maturation ... Biochemistry. 2011 Feb 8;50(5):672-85. Epub 2011 Jan 11. Loo TW, Bartlett MC, Clarke DM
The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants.
Biochemistry. 2011 Feb 8;50(5):672-85. Epub 2011 Jan 11., 2011-02-08 [PMID:21182301]
Abstract [show]
ATP-binding cassette (ABC) proteins contain two nucleotide-binding domains (NBDs) and two transmembrane (TM) domains (TMDs). Interdomain interactions and packing of the TM segments are critical for function, and disruption by genetic mutations contributes to disease. P-glycoprotein (P-gp) is a useful model to identify mechanisms that repair processing defects because numerous arginine suppressor mutations have been identified in the TM segments. Here, we tested the prediction that a mechanism of arginine rescue was to promote intradomain interactions between TM segments and restore interdomain assembly. We found that suppressor W232R(TM4/TMD1) rescued mutants with processing mutations in any domain and restored defective NBD1-NBD2, NBD1-TMD2, and TMD1-TMD2 interactions. W232R also promoted packing of the TM segments because it rescued a truncation mutant lacking both NBDs. The mechanism of W232R rescue likely involved intradomain hydrogen bond interactions with Asn296(TM5) since only N296A abolished rescue by W232R and rescue was only observed when Trp232 was replaced with hydrogen-bonding residues. In TMD2, suppressor T945R(TM11) also promoted packing of the TM segments because it rescued the truncation mutant lacking the NBDs and suppressed formation of alternative topologies. We propose that T945R rescue was mediated by interactions with Glu875(TM10) since T945E/E875R promoted maturation while T945R/E875A did not.
Comments [show]
None has been submitted yet.
No. Sentence Comment
309 It was not surprising that the mutations affected rhodamine B-stimulated ATPase activity because it was previously shown that treatment of mutants W232C, N296C, and T945C (E875C was not tested) with a thiol-reactive analogue of rhodamine inhibited activity (15).
X
ABCB1 p.Asn296Cys 21182301:309:154
status: NEW368 These results are consistent with those from cysteine mutagenesis studies where modification of mutant T945C by thiol-reactive analogues of verapamil or rhodamine or mutants W232C and N296C by a thiol reactive analogue of rhodamine inhibited their activity (13, 15).
X
ABCB1 p.Asn296Cys 21182301:368:184
status: NEW